Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 34 of 36.
Apr 2010
5 Apr · Updates
Pursuant to a business restructuring between CIMAB S.A and Biocon Limited ('Company'), Biocon SA, a wholly subsidiary of the Company has entered into an agreement to acquire the 49% equity stake held by CIMAB SA in Biocon Biopharmaceuticals Private Limited ('BBPL'). Post this acquisition, BBPL will become a wholly owned subsidiary of the Company. The Company and CIMAB shall continue their partnership on research, development and commercialization of a range of novel biopharmaceutical products5 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the Company for the year ended on March 31, 2010 and to consider recommendation of payment of dividend, if any, for the year 2009-2010.
Mar 2010
22 Mar · Business
Press release dated March 22, 2010, titled "Syngene to Collaborate with Endo Pharmaceuticals to Develop Anti-cancer Novel Therapeutic Molecules". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
4 Feb · Business
Press release dated February 04, 2010, titled " Biocon and Bayer join hands to create awareness for self monitoring in diabetics". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
22 Jan · Business
Press release dated January 22, 2010 titled "Biocon Explores Investment in Malaysia in partnership with Biotechcorp". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Business
Press release dated January 21, 2010 titled "Biocon Limited Announces Results for the Nine Months Ended December 31, 2009; Revenues at Rs 1,739 crores; EBITDA at Rs 369 crores; PAT at Rs 213 crores". Further a copy of the press release along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 30083 lacs for quarter ending on 31-DEC-2009 against Rs. 21987 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 6580 lacs for the quarter ending on 31-DEC-2009 against Rs. 2408 lacs for the quarter ending on 31-DEC-2008.21 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 63512 lacs for quarter ending on 31-DEC-2009 against Rs. 43619 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 8089 lacs for the quarter ending on 31-DEC-2009 against Rs. 2820 lacs for the quarter ending on 31-DEC-2008.1 Jan · Board meeting
Inter-alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2009.
Dec 2009
10 Dec · Business
Press release dated December 10, 2009, titled "Biocon and HCG Group of Hospitals Ltd join hands to fight against Cervical Cancer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Dec · Updates
Biocon Limited had informed the Exchange regarding the execution of a definitive agreement. The Company has now informed the Exchange that the Company has completed the acquisition formalities of the bulk pharmaceutical business undertaking of M/s IDL Specialty Chemicals Limited, located near Hyderabad.
Oct 2009
29 Oct · Disclosure
Company have received an intimation on October 28, 2009 under Form C, pursuant to Regulation 13(3) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (Annexure I) from HDFC Asset Management Company Limited that there is a decrease in their holdings by 2.054% and the aggregate holding of the schemes of HDFC Mutual Fund in the company is 5.139% of the paid up share capital of Biocon Limited. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Oct · Business
Press release dated October 22, 2009 titled "Biocon Limited Announces Results for the Half-Year Ended September 30, 2009; Revenues rise to Rs 1,098 crores; EBITDA at Rs.236 crores; PAT at Rs 132 crores". Further a copy of the press release along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Oct · Results
Standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 53494 lacs for half year ending on 30-SEP-2009 against Rs. 46788 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 10991 lacs for the half year ending on 30-SEP-2009 against Rs. 6352 lacs for the half year ending on 30-SEP-2008.22 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 29215 lacs for quarter ending on 30-SEP-2009 against Rs. 24670 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6236 lacs for the quarter ending on 30-SEP-2009 against Rs. 3353 lacs for the quarter ending on 30-SEP-2008.22 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 57993 lacs for quarter ending on 30-SEP-2009 against Rs. 43930 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 7419 lacs for the quarter ending on 30-SEP-2009 against Rs. 2502 lacs for the quarter ending on 30-SEP-2008.22 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 107586 lacs for half year ending on 30-SEP-2009 against Rs. 70323 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 13174 lacs for the half year ending on 30-SEP-2009 against Rs. 4006 lacs for the half year ending on 30-SEP-2008.1 Oct · Board meeting
Meeting on 22 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Sep 2009
30 Sep · Business
Company has entered into a definitive agreement, to acquire the bulk pharmaceutical business undertaking of IDL Specialty Chemicals Limited located near Hyderabad, subject to the closing conditions detailed in the said agreement.29 Sep · Business
Press release dated September 29, 2009, titled "Kiran Mazumdar Shaw in Financial Times' 'Top 50 women in business' list". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Sep · Business
Vide its letter dated September 24, 2009 regarding a press release dated September 23, 2009, titled "Biocon among 20 Indian companies in Forbes 'Best Under A Billion' list". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Sep · Business
Press release dated September 11, 2009, titled "Biocon Limited and Amylin Pharmaceuticals Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
20 Aug · Business
Press release dated August 20, 2009, titled "Kiran Mazumdar Shaw features on the Forbes list of The World's 100 Most Powerful Women". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Business
Vide its letter dated August 11, 2009, regarding a press release dated August 10, 2009 titled "The Syngene Vivarium receives official accreditation by AAALAC". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
24 Jul · Meeting
Proceedings of the Annual General Meeting of the Company held on July 23, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Business
Press release dated July 23, 2009 titled "Biocon's Q1 FY ' 10 Results Surge Ahead Revenues Rs.505 crores. EBITDA Rs.111crores. PAT Rs.58 crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 24279 lacs for quarter ending on 30-JUN-2009 against Rs. 22118 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 4755 lacs for the quarter ending on 30-JUN-2009 against Rs. 3001 lacs for the quarter ending on 30-JUN-2008.23 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 49593 lacs for quarter ending on 30-JUN-2009 against Rs. 26393 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 5755 lacs for the quarter ending on 30-JUN-2009 against Rs. 1502 lacs for the quarter ending on 30-JUN-2008.6 Jul · Board meeting
Meeting on 23 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Jun 2009
29 Jun · Business
Press release dated June 29, 2009, titled "Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jun · Corporate action
Biocon Limited had informed the Exchange that the Company has announce the Book Closure from July 15, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend. The Company has now informed the Exchange that the company has revised the book closure dates as follows: The company has announce the Book Closure from July 10, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend.22 Jun · Meeting
Company has announce the Book Closure from July 15, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend.8 Jun · Business
Press release dated June 08, 2009, titled "Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management ; Initial contribution of Rs. 1 crore to set up the cell". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
29 May · Business
Press release dated May 29, 2009, titled "Biocon launches BASALOG(TM) - long lasting basal insulin for Type 1 & Type 2 Diabetics". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 May · Business
Press release dated May 11, 2009 titled "Kiran Mazumdar Shaw awarded the prestigious 'Nikkei Asia Prize' 2009 for Regional Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
28 Apr · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 91234 lacs for year ending on 31-MAR-2009 against Rs. 87693 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 11181 lacs for the year ending on 31-MAR-2009 against Rs. 43494 lacs for the year ending on 31-MAR-2008.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 22160 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 2414 lacs for the quarter ending on 31-MAR-2009.28 Apr · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 160867 lacs for year ending on 31-MAR-2009 against Rs. 105379 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 9312 lacs for the year ending on 31-MAR-2009 against Rs. 46391 lacs for the year ending on 31-MAR-2008.28 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 46626 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 2488 lacs for the quarter ending on 31-MAR-2009.28 Apr · Business
Press release dated April 28, 2009 titled "Biocon Group Delivers 16% Growth in Operating Profits - PAT Impacted By MTM. Board Recommends Rs.3 per share (60%) As Dividend ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Dividend
Board of Directors of the Company at its meeting held on April 28, 2009 have recommended, subject to the approval of the members dividend of 60% (Rs. 3) per share on the enhanced share capital of the company.1 Apr · Board meeting
To approve and take on record the audited financial results of the company for the year ended on March 31, 2009 and to consider recommendation of payment of dividend, if any, for the year 2008-2009
Mar 2009
23 Mar · Business
Press release, dated March 23, 2009, titled "Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Business
Press release, dated March 18, 2009, titled "Biocon wins prestigious 2009 BioSingapore Asia Pacific Biotechnology Award for Best Listed Company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Mar · Business
Press release issued by Syngene International Limited ("Syngene") a subsidiary of the Company, dated March 09, 2009, titled "Syngene and DuPont Crop Protection Forge Alliance Partnership". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Business
Press release issued by Axicorp GmbH ("Axicorp"), a Biocon Company, which has been released at Friedrichsdorf, Germany, dated March 02, 2009, titled "Axicorp Press Release". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
21 Jan · Business
Press release issued by Syngene International Limited ("Syngene") a wholly owned subsidiary of the Company, dated January 21, 2009, titled "Syngene partners with Sapient Discovery to expand integrated drug discovery offerings". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Business
Press release dated January 21, 2009 titled "Biocon's 9 months FY-09 maintains growth momentum, Revenues : Rs. 1,187 crs (including AxiCorp) : Rs. 889 crs (excluding AxiCorp) : EBITDA Rs. 277 crs : PAT Rs. 174 crs (excluding MTM)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 21987 lacs for quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 2408 lacs for the quarter ending on 31-DEC-2008.21 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 43619 lacs for quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 2820 lacs for the quarter ending on 31-DEC-2008.